Rand Wealth LLC reduced its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 15.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,345 shares of the medical research company’s stock after selling 250 shares during the period. Rand Wealth LLC’s holdings in Amgen were worth $221,000 as of its most recent filing with the SEC.
Several other large investors have also bought and sold shares of AMGN. Norges Bank acquired a new stake in Amgen during the fourth quarter valued at approximately $1,016,913,000. FMR LLC raised its stake in Amgen by 11.3% in the fourth quarter. FMR LLC now owns 40,789,786 shares of the medical research company’s stock valued at $5,963,875,000 after buying an additional 4,144,154 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new stake in Amgen during the fourth quarter valued at approximately $275,209,000. Asset Management One Co. Ltd. raised its stake in Amgen by 426.2% in the fourth quarter. Asset Management One Co. Ltd. now owns 1,331,811 shares of the medical research company’s stock valued at $194,885,000 after buying an additional 1,078,691 shares in the last quarter. Finally, State Street Corp raised its stake in Amgen by 2.8% in the fourth quarter. State Street Corp now owns 34,308,673 shares of the medical research company’s stock valued at $5,016,268,000 after buying an additional 919,966 shares in the last quarter. Institutional investors and hedge funds own 78.84% of the company’s stock.
Shares of Amgen Inc. (NASDAQ AMGN) opened at 165.09 on Tuesday. The firm’s 50-day moving average is $160.21 and its 200 day moving average is $161.24. The firm has a market capitalization of $121.41 billion, a PE ratio of 15.68 and a beta of 1.37. Amgen Inc. has a 52 week low of $133.64 and a 52 week high of $184.21.
Amgen (NASDAQ:AMGN) last announced its earnings results on Wednesday, April 26th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.00 by $0.15. The business had revenue of $5.46 billion for the quarter, compared to analyst estimates of $5.60 billion. Amgen had a net margin of 34.42% and a return on equity of 29.37%. The company’s revenue for the quarter was down 1.1% compared to the same quarter last year. During the same period last year, the firm posted $2.90 earnings per share. On average, equities analysts forecast that Amgen Inc. will post $12.43 earnings per share for the current year.
A number of research analysts have recently issued reports on AMGN shares. Jefferies Group LLC downgraded shares of Amgen from a “buy” rating to a “hold” rating and cut their price objective for the stock from $194.00 to $180.00 in a research report on Wednesday, April 5th. Vetr raised shares of Amgen from a “buy” rating to a “strong-buy” rating and set a $184.82 price objective on the stock in a research report on Monday, March 27th. Credit Suisse Group reaffirmed a “hold” rating and issued a $178.00 price objective on shares of Amgen in a research report on Tuesday, April 4th. Cowen and Company reaffirmed an “outperform” rating and issued a $209.00 price objective on shares of Amgen in a research report on Wednesday, April 19th. Finally, Mizuho set a $195.00 price objective on shares of Amgen and gave the stock a “buy” rating in a research report on Thursday, March 16th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. Amgen has an average rating of “Buy” and a consensus target price of $185.49.
In other news, SVP Cynthia M. Patton sold 2,922 shares of the firm’s stock in a transaction that occurred on Wednesday, May 24th. The shares were sold at an average price of $154.40, for a total transaction of $451,156.80. Following the transaction, the senior vice president now directly owns 24,214 shares in the company, valued at $3,738,641.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.20% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.